Precision Oncology Sector Sees Transformation with Biomarker-Driven Therapies and Immunotherapies.
ByAinvest
Wednesday, Nov 19, 2025 9:51 am ET1min read
ALXO--
ERAS--
IMRX--
ONCY--
The precision oncology sector is experiencing significant growth, with a market value of $106.21 billion in 2025 and an 11% compound annual rate. Biomarker-driven therapies and platform immunotherapies are transforming cancer treatment paradigms, particularly for historically difficult cancers. Companies like Oncolytics Biotech, ALX Oncology, Erasca, Immuneering, and Prelude Therapeutics are leading the charge with targeted therapies for gastrointestinal, blood, and solid tumor cancers.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet